Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The company recently completed a massive expansion in Durham and is acquiring a Raleigh company for billions. Join us as we honor outstanding C-Level Executives for their invaluable contributions to ...

At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal ...

Biogen Inc. (NASDAQ: BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a ...

"While U.S. POINTER was designed and powered as a head-to-head comparison of the two interventions, and a statistically ...

Triangle gets props for having one of the strongest job markets. But another booming region of North Carolina ranks higher.

Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their products. The EMA's Committee for Medicinal ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...